middle.news
Mesoblast Secures A$260M to Propel Ryoncil® US Launch and Clinical Trials
10:09am on Tuesday 14th of January, 2025 AEDT
•
Biotechnology
Read Story
Mesoblast Secures A$260M to Propel Ryoncil® US Launch and Clinical Trials
10:09am on Tuesday 14th of January, 2025 AEDT
Key Points
A$260 million raised at A$2.50 per share via global private placement
Funds allocated for US launch of Ryoncil® for pediatric steroid-refractory acute graft-versus-host disease
Acceleration of second Phase 3 trial for inflammatory chronic low back pain
Expansion of commercial manufacturing capabilities in anticipation of product demand
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Mesoblast (ASX:MSB)
OPEN ARTICLE